EN
Pipeline & Strategy
Home >Innovation >Pipeline & Strategy
Pipeline
CanSinoBIO is dedicated in innovation and has established a diversified portfolio of product candidates preventing more than 10 diseases, demonstrating strong competitiveness.
Globally Innovative First-in-class in China Pre-clinical Innovative
Strategy
The increasing demand for combination vaccines is expected to drive our business growth.
Meningococcal Vaccine Products
  • Groups A and C Meningococcal Polysaccharide Conjugate Vaccine (CRM197) Menphecia®
  • Groups ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) Menhycia®
  • CS-2023 Meningococcal vaccine
Pneumococcal Vaccine Products
  • PCV13i (CRM197/TT Double vector)
  • PBPV
  • CS-2028 Multivalent Pneumococcal Conjugate Vaccine
DTP Vaccine Products
  • DTcP Infant
  • Tdcp Adolescent and Adult
  • CS-2201 DTcP Components Combined Vaccine
Other
  • TB Booster
  • Recombinant Zoster Vaccine (Adenovirus Vector)
  • Absorbed Tetanus Vaccine
  • Recombinant Poliomyelitis vaccine
  • Haemophilus Influenzae Type b Conjugate Vaccine, Freeze-dried